• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The PLATO trial: Ticagrelor vs clopidogrel for ACS [Classics Series]

byAndrew Cheung, MD MBA
November 9, 2014
in Emergency Classics, General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with ticagrelor significantly reduces mortality in patients with acute coronary syndrome when compared to clopidogrel.

2. Ticagrelor does not significantly increase the incidence of major bleeding.

Original Date of Publication: September 2009

Study Rundown: Clopidogrel is a commonly used medication in the management of acute coronary syndromes (ACS). A previous study comparing prasugrel, another oral antiplatelet agent, with clopidogrel demonstrated a significant reduction in the risk of coronary thrombotic events, but no improvement in mortality. The Platelet Inhibition and Patient Outcomes (PLATO) trial compared the use of ticagrelor, a newer and more potent oral platelet inhibitor, with clopidogrel in treating patients with ACS. In summary, patients treated with ticagrelor experienced significantly lower rates of death from vascular causes, myocardial infarction, or stroke at 12 months when compared to patients on clopidogrel (HR 0.84; 95%CI 0.77-0.92). This was driven by both significant reductions in the rate of death from vascular causes and myocardial infarction. Moreover, there was no significant difference between the two groups in the rate of major bleeding (HR1.04; 95%CI 0.95-1.13).

Click to read study in NEJM

In-Depth [randomized, controlled study]: Originally published in 2009 in NEJM, this study was a multicenter trial, which randomized patients to treatment with clopidogrel or ticagrelor in addition to aspirin after ACS. Patients were eligible for the study if they were hospitalized for ACS with or without ST-segment elevation, with symptom onset in the previous 24 hours. Patients were excluded if they had contraindications to clopidogrel, they received fibrinolytic therapy in the 24 hours prior to randomization, they needed oral anticoagulation, they had an increased risk of bradycardia, or they were being treated with a strong cytochrome P-450 3A inhibitor or inducer. The primary endpoint was a composite of death from vascular causes, myocardial infarction, or stroke. Major life-threatening bleeding was defined as fatal bleeding, intracranial bleeding, intrapericardial bleeding with cardiac tamponade, shock/hypotension as a result of bleeding, hemoglobin decrease ≥5.0 g/dL, or need for transfusion of ≥4 units of packed red blood cells.

A total of 18,624 patients were recruited from 862 centres in 43 countries. At 12 months, the primary endpoint occurred significantly less in the ticagrelor group as compared with the clopidogrel group (HR 0.84; 95%CI 0.77-0.92). This difference was driven by significant reductions in rates of myocardial infarction (HR 0.84; 95%CI 0.75-0.95) and death from vascular causes (HR 0.79; 95%CI 0.69-0.91) in the ticagrelor group. The rates of major bleeding were not significantly different between the two groups (HR 1.04; 95%CI 0.95-1.13). Notably, the rate of fatal intracranial bleeding was significantly higher in the ticagrelor group compared to the clopidogrel group (p=0.02).

RELATED REPORTS

Treatment with clopidogrel with aspirin or ticagrelor with aspirin produces similar risk reduction of stroke recurrence or death

Oral P2Y12 inhibitor pretreatment offers no benefit in non-ST elevation acute coronary syndromes

De-escalation with clopidogrel may reduce bleeding events in patients with recent percutaneous coronary intervention

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: clopidogrelPLATOTicagrelor
Previous Post

HIV-infected infant potentially cured with antiretroviral therapy

Next Post

Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

RelatedReports

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Emergency

Treatment with clopidogrel with aspirin or ticagrelor with aspirin produces similar risk reduction of stroke recurrence or death

December 9, 2021
Propofol appears safe and effective in procedural sedation for cardioversion
Cardiology

Oral P2Y12 inhibitor pretreatment offers no benefit in non-ST elevation acute coronary syndromes

May 13, 2022
Colchicine may lower the risk of cardiovascular events in patients with coronary disease
Cardiology

De-escalation with clopidogrel may reduce bleeding events in patients with recent percutaneous coronary intervention

October 19, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Clopidogrel monotherapy is superior to aspirin monotherapy for chronic maintenance after percutaneous coronary intervention

July 7, 2021
Next Post
Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

CTA as an alternative to angiography for blunt cerebrovascular trauma detection

Decreased stroke incidence in high-income countries, decreased mortality worldwide (1990-2010)

Influenza vaccine associated with lower risk of major cardiovascular events

2 Minute Medicine Rewind October 20th – October 27th, 2013

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.